Genzyme, Impax Bury Hatchet Over Kidney Disease Drugs

Law360, New York (September 5, 2012, 7:39 PM EDT) -- Impax Laboratories Inc. on Tuesday settled patent infringement claims brought by Sanofi-Aventis SA subsidiary Genzyme Corp. over plans to make generic versions of two Genzyme kidney disease treatments, reaching a deal that will give Impax licensing rights in 2014.

Under the agreement, Impax may sell generic Renagel tablets in 400-milligram and 800-milligram dosages and generic Renvela liquid treatments in 2.4-gram and 0.8-gram dosages effective Sept. 16, 2014. Impax may sell generic Renvela 800-milligram tablets effective March 16, 2014.   

Tuesday’s settlement ends a protracted litigation battle...
To view the full article, register now.